Patient characteristics
| . | N . | 5-y incidence of relapse in % (SD)¶ . | P value for association with ALL relapse . |
|---|---|---|---|
| Treatment protocol | 1.35 × 10−14# | ||
| COG P9904/9905 | 1606 | 14.4 (0.89) | |
| COG P9906 | 222 | 33.5 (3.22) | |
| St Jude Total Therapy XIIIB | 222 | 12.2 (2.21) | |
| St Jude Total Therapy XV | 485 | 8.97 (1.35) | |
| Self-reported race/ethnicity* | .0052 | ||
| Asian | 76 | 20.8 (4.85) | |
| Black | 251 | 15.1 (2.29) | |
| Hispanic | 405 | 20.7 (2.05) | |
| Others | 116 | 17.0 (3.58) | |
| White | 1687 | 13.1 (0.84) | |
| Sex | .0094 | ||
| Female | 1163 | 13.1 (1.01) | |
| Male | 1372 | 16.4 (1.02) | |
| Age at diagnosis, y | 2.37 × 10−9 | ||
| < 10 | 1998 | 12.7 (0.76) | |
| ≥ 10 | 537 | 23.4 (1.87) | |
| Leukocyte count at diagnosis,/μL | 1.11 × 10−10 | ||
| < 50 000 | 2104 | 12.9 (0.75) | |
| ≥ 50 000 | 431 | 24.8 (2.11) | |
| CNS status† | .56 | ||
| CNS3 or traumatic | 86 | 17.0 (4.21) | |
| CNS1 | 2124 | 14.4 (0.78) | |
| CNS2 | 324 | 17.8 (2.17) | |
| Missing | 1 | 0 (0) | |
| Lineage and molecular subtype of ALL | 1.16 × 10−6 | ||
| B-other | 1673 | 16.0 (0.92) | |
| BCR-ABL | 14 | 53.6 (15.77) | |
| TCF3-PBX1 | 126 | 16.1 (3.3) | |
| MLL rearrangement | 29 | 31.2 (8.83) | |
| T cell | 109 | 19.5 (3.85) | |
| ETV6-RUNX1 | 584 | 9 (1.2) | |
| DNA index‡ | 1.04 × 10−5 | ||
| < 1.16 | 1798 | 16.7 (0.9) | |
| ≥ 1.16 | 682 | 10.6 (1.21) | |
| Missing | 55 | 9.1 (3.93) | |
| End-of-induction MRD§ | 1 × 10−16 | ||
| < 0.01% | 1835 | 10.1 (0.72) | |
| ≥ 0.01% & < 1% | 373 | 30.9 (2.45) | |
| ≥ 1% | 81 | 59.8 (5.89) | |
| Missing | 246 | 12.5 (2.13) |
| . | N . | 5-y incidence of relapse in % (SD)¶ . | P value for association with ALL relapse . |
|---|---|---|---|
| Treatment protocol | 1.35 × 10−14# | ||
| COG P9904/9905 | 1606 | 14.4 (0.89) | |
| COG P9906 | 222 | 33.5 (3.22) | |
| St Jude Total Therapy XIIIB | 222 | 12.2 (2.21) | |
| St Jude Total Therapy XV | 485 | 8.97 (1.35) | |
| Self-reported race/ethnicity* | .0052 | ||
| Asian | 76 | 20.8 (4.85) | |
| Black | 251 | 15.1 (2.29) | |
| Hispanic | 405 | 20.7 (2.05) | |
| Others | 116 | 17.0 (3.58) | |
| White | 1687 | 13.1 (0.84) | |
| Sex | .0094 | ||
| Female | 1163 | 13.1 (1.01) | |
| Male | 1372 | 16.4 (1.02) | |
| Age at diagnosis, y | 2.37 × 10−9 | ||
| < 10 | 1998 | 12.7 (0.76) | |
| ≥ 10 | 537 | 23.4 (1.87) | |
| Leukocyte count at diagnosis,/μL | 1.11 × 10−10 | ||
| < 50 000 | 2104 | 12.9 (0.75) | |
| ≥ 50 000 | 431 | 24.8 (2.11) | |
| CNS status† | .56 | ||
| CNS3 or traumatic | 86 | 17.0 (4.21) | |
| CNS1 | 2124 | 14.4 (0.78) | |
| CNS2 | 324 | 17.8 (2.17) | |
| Missing | 1 | 0 (0) | |
| Lineage and molecular subtype of ALL | 1.16 × 10−6 | ||
| B-other | 1673 | 16.0 (0.92) | |
| BCR-ABL | 14 | 53.6 (15.77) | |
| TCF3-PBX1 | 126 | 16.1 (3.3) | |
| MLL rearrangement | 29 | 31.2 (8.83) | |
| T cell | 109 | 19.5 (3.85) | |
| ETV6-RUNX1 | 584 | 9 (1.2) | |
| DNA index‡ | 1.04 × 10−5 | ||
| < 1.16 | 1798 | 16.7 (0.9) | |
| ≥ 1.16 | 682 | 10.6 (1.21) | |
| Missing | 55 | 9.1 (3.93) | |
| End-of-induction MRD§ | 1 × 10−16 | ||
| < 0.01% | 1835 | 10.1 (0.72) | |
| ≥ 0.01% & < 1% | 373 | 30.9 (2.45) | |
| ≥ 1% | 81 | 59.8 (5.89) | |
| Missing | 246 | 12.5 (2.13) |
Self-reported race/ethnicity was assigned based on clinical trial databases.
CNS status indicates the level of leukemia in the CNS at diagnosis.
DNA index represents the ratio of DNA content of leukemia sample per diploid human normal control, an indicator of aneuploidy in tumors.
MRD was determined at day 29 in the COG cohorts and at day 46 in the St Jude cohorts, as described in “Association of SNPs with additional prognostic phenotypes.”
Relapse is defined as leukemia recurrence in bone marrow and/or extramedullary tissues.
Association between patient characteristics and relapse risk was determined using the Gray test in univariate analyses.